Merck's ADC Achieves 100% Response in Lymphoma Trials
TL;DR Summary
Merck & Co. has reported promising phase 2 trial results for its ROR1-directed antibody-drug conjugate (ADC), zilovertamab vedotin, showing a 100% complete response rate in patients with diffuse large B-cell lymphoma (DLBCL) at certain doses. Despite some safety concerns at higher doses, the company plans to advance the low dose into a phase 3 trial, comparing it to the standard R-CHOP regimen. The trial will focus on progression-free survival as the primary endpoint, with complete response and overall survival as secondary endpoints.
- Merck ADC RORs into phase 3 with 100% complete response rate Fierce Biotech
- Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL OncLive
- ASH: MSD’s ROR1 drug hits the target in first-line lymphoma pharmaphorum
- Merck’s investigational ADC with R-CHP demonstrates 100% response rate for B-cell lymphoma Indian Pharma Post
- Merck: encouraging results in diffuse lymphoma Marketscreener.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
83%
493 → 82 words
Want the full story? Read the original article
Read on Fierce Biotech